CEP55 基因作为 LUAD 和 LUSC 诊断生物标志物和独立预后因素的价值。
The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
机构信息
The Department of Thoracic and Cardiovascular Surgery, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, Republic of China.
出版信息
PLoS One. 2020 May 21;15(5):e0233283. doi: 10.1371/journal.pone.0233283. eCollection 2020.
OBJECTIVE
To investigate the value of CEP55 as a diagnostic marker and independent prognostic factor in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), and to analyze its co-expression genes and related signaling pathways.
METHODS
TCGA database and GEO database were used to analyze the expression of CEP55 in LUAD and LUSC compared with normal tissues. The co-expression genes of CEP55 in LUAD and LUSC were excavated by cBioPortal and enriched by KEGG and GO. Establishing Receiver operating characteristic (ROC) curve to evaluate the value of CEP55 as a diagnostic and prognostic factor. The association between CEP55 expression and the clinicopathological features was evaluated using χ2 tests. ROC curves for diagnosis and prognosis detection were constructed. Prognostic values were analyzed by univariate and multivariate Cox regression models.
RESULTS
Compared with normal lung tissues, CEP55 expression was significantly upregulated in both LUAD and LUSC. ROC curve analysis showed that CEP55 could be used as an effective diagnostic target for LUAD (AUC = 0.969) and LUSC (AUC = 0.994). When CEP55 gene was selected as an independent prognostic factor, high expression of CEP55 was more disadvantageous to OS and RFS of LUAD patients (P<0.05), but no significant difference was found in LUSC patients (P>0.05). The number of co-expression genes of CEP55 in LUAD is more than that in LUSC, and is related to cell cycle, DNA replication and P53 signaling pathway.
CONCLUSION
CEP55 can be used as a diagnostic marker for LUAD and LUSC, but only as an independent prognostic factor for LUAD rather than LUSC.
目的
探讨 CEP55 作为肺腺癌（LUAD）和鳞状细胞癌（LUSC）诊断标志物和独立预后因子的价值，并分析其共表达基因及相关信号通路。
方法
利用 TCGA 数据库和 GEO 数据库分析 CEP55 在 LUAD 和 LUSC 组织与正常组织中的表达差异。通过 cBioPortal 挖掘 LUAD 和 LUSC 中 CEP55 的共表达基因，并通过 KEGG 和 GO 进行富集分析。构建受试者工作特征（ROC）曲线评估 CEP55 作为诊断和预后因子的价值。采用卡方检验评估 CEP55 表达与临床病理特征的相关性。构建 ROC 曲线用于诊断和预后检测。采用单因素和多因素 Cox 回归模型分析预后价值。
结果
与正常肺组织相比，CEP55 在 LUAD 和 LUSC 中均呈显著高表达。ROC 曲线分析表明，CEP55 可作为 LUAD（AUC=0.969）和 LUSC（AUC=0.994）的有效诊断靶标。当 CEP55 基因被选为独立预后因子时，CEP55 高表达对 LUAD 患者的 OS 和 RFS 更为不利（P<0.05），但在 LUSC 患者中未发现显著差异（P>0.05）。CEP55 在 LUAD 中的共表达基因数量多于 LUSC，与细胞周期、DNA 复制和 P53 信号通路相关。
结论
CEP55 可作为 LUAD 和 LUSC 的诊断标志物，但仅作为 LUAD 的独立预后因子，而非 LUSC。
Zotero 插件